Cano Health Stock Jumps Premarket On Annual Guidance Hike

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Cano Health Inc (NYSE:CANO) has announced Q2 revenue of $393.2 million, +130% Y/Y, compared to $171.20 million a year ago, driven by acquisitions and membership growth.
The total membership of 156,038, including Medicare capitated members, reached 111,866, +57% and 54%, respectively.
Adjusted EBITDA increased to $24.8 million from $16.2 million a year ago. Reported net income of $4.9 million compared to a net loss of $11.0 million.
The medical claims expense ratio was 77.0%, compared to 73.0% in Q1 FY21, due to the inclusion of Direct Contracting Entity (DCE) members who we initially expect to have higher medical costs, and, to a lesser extent, by higher elective procedure utilization and costs related to COVID-19.
Cano Health had $319 million of cash, cash equivalents, and restricted cash at the end of the quarter.
FY21 Guidance: Cano increased membership guidance to approximately 215,000, up from 205,000 - 210,000 previously.
It expects revenue of about $1.6 billion, better than consensus and guidance of $1.5 billion. It forecasts adjusted EBITDA of $115 million versus $110 million previously and reaffirms to open 15 to 20 de novo medical centers in 2021
FY22 Guidance: Cano sees sales of $2.5 billion - $2.6 billion (consensus $2.15 billion), an increase from the prior guidance of approximately $2.23 billion.
It expects adjusted EBITDA of $165 million - $170 million, up from the prior outlook of $150 million.
Price Action: CANO shares are up 12.10% at $11.95 during the premarket session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.